{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:09:01Z","timestamp":1791230941514,"version":"4.1.0"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":138,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001799","name":"Murdoch University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001799","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Clostridium (Clostridioides) difficile infection (CDI) remains an urgent threat to patients in health systems worldwide. Recurrent CDI occurs in up to 30% of cases due to sustained dysbiosis of the gut microbiota which normally protects against CDI. Associated costs of initial and recurrent episodes of CDI impose heavy financial burdens on health systems. Vancomycin and metronidazole have been the mainstay of therapy for CDI for many years; however, these agents continue to cause significant disruption to the gut microbiota and thus carry a high risk of recurrence for CDI patients. Treatment regimens are now turning towards novel narrow spectrum antimicrobial agents which target C. difficile while conserving the commensal gut microbiota, thus significantly reducing risk of recurrence. One such agent, fidaxomicin, has been in therapeutic use for several years and is now recommended as a first-line treatment for CDI, as it is superior to vancomycin in reducing risk of recurrence. Another narrow spectrum agent, ridnilazole, was recently developed and is undergoing evaluation of its potential clinical utility. This review aimed to summarize experimental reports of ridinilazole and assess its potential as a first-line agent for treatment of CDI. Reported results from in vitro assessments, and from hamster models of CDI, show potent activity against C. difficile, non-inferiority to vancomycin for clinical cure and non-susceptibility among most gut commensal bacteria. Phase I and II clinical trials have been completed with ridinilazole showing high tolerability and efficacy in treatment of CDI, and superiority over vancomycin in reducing recurrence of CDI within 30 days of treatment completion. Phase III trials are currently underway, the results of which may prove its potential to reduce recurrent CDI and lessen the heavy health and financial burden C. difficile imposes on patients and healthcare systems.<\/jats:p>","DOI":"10.1111\/lam.13664","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T09:00:38Z","timestamp":1643965238000},"page":"526-536","source":"Crossref","is-referenced-by-count":23,"title":["Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6754-9290","authenticated-orcid":false,"given":"Deirdre A","family":"Collins","sequence":"first","affiliation":[{"name":"School of Medical and Health Sciences Edith Cowan University Joondalup Western Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1351-3740","authenticated-orcid":false,"given":"Thomas V.","family":"Riley","sequence":"additional","affiliation":[{"name":"School of Medical and Health Sciences Edith Cowan University Joondalup Western Australia"},{"name":"Department of Microbiology PathWest Laboratory Medicine Nedlands Western Australia"},{"name":"Medical, Molecular and Forensic Sciences Murdoch University Murdoch Western Australia Australia"},{"name":"School of Biomedical Sciences The University of Western Australia Queen Elizabeth II Medical Centre Nedlands WA Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"2023011712242342100_lam13664-bib-0001","volume-title":"Clostridioides difficile infection: 2018 data snapshot","author":"ACSQHC","year":"2020"},{"key":"2023011712242342100_lam13664-bib-0002","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.diagmicrobio.2015.05.015","article-title":"A national survey of the molecular epidemiology of Clostridium difficile in Israel: the dissemination of the ribotype 027 strain with reduced susceptibility to vancomycin and metronidazole","volume":"83","author":"Adler","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023011712242342100_lam13664-bib-0003","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1128\/JCM.01964-07","article-title":"Increased sporulation rate of epidemic Clostridium difficile Type 027\/NAP1","volume":"46","author":"Akerlund","year":"2008","journal-title":"J Clin Microbiol"},{"key":"2023011712242342100_lam13664-bib-0004","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1128\/JCM.01810-15","article-title":"Infection with toxin A-negative, toxin B-negative, binary toxin-positive Clostridium difficile in a young patient with ulcerative colitis","volume":"53","author":"Androga","year":"2015","journal-title":"J Clin Microbiol"},{"key":"2023011712242342100_lam13664-bib-0005","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jac\/dku324","article-title":"SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model","volume":"70","author":"Baines","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2023011712242342100_lam13664-bib-0006","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/0016-5085(78)90457-2","article-title":"Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis","volume":"75","author":"Bartlett","year":"1978","journal-title":"Gastroenterology"},{"key":"2023011712242342100_lam13664-bib-0007","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/jac\/dkv498","article-title":"Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection","volume":"71","author":"Basseres","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2023011712242342100_lam13664-bib-0008","volume-title":"Antibiotic resistance threats in the United States, 2019","author":"CDC","year":"2019"},{"key":"2023011712242342100_lam13664-bib-0009","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/jac\/dkaa522","article-title":"Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile","volume":"76","author":"Collins","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023011712242342100_lam13664-bib-0010","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jac\/dkv006","article-title":"In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile","volume":"70","author":"Corbett","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2023011712242342100_lam13664-bib-0011","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2023011712242342100_lam13664-bib-0012","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1473-3099(14)70991-0","article-title":"Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID)","volume":"14","author":"Davies","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"Supplement 2","key":"2023011712242342100_lam13664-bib-0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12418","article-title":"European Society of Clinical Microbiology and Infectious Diseases: Update of the treatment guidance document for Clostridium difficile infection","volume":"20","author":"Debast","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2023011712242342100_lam13664-bib-0014","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1086\/678428","article-title":"Attributable inpatient costs of recurrent Clostridium difficile infections","volume":"35","author":"Dubberke","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2023011712242342100_lam13664-bib-0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nmni.2014.10.003","article-title":"Prevalence and pathogenicity of binary toxin\u2013positive Clostridium difficile strains that do not produce toxins A and B","volume":"3","author":"Eckert","year":"2015","journal-title":"New Microbes and New Infections"},{"key":"2023011712242342100_lam13664-bib-0016","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/AAC.02000-15","article-title":"Susceptibility of Clostridium difficile isolates of varying antimicrobial resistance phenotypes to SMT19969 and 11 comparators","volume":"60","author":"Freeman","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023011712242342100_lam13664-bib-0017","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10096-019-03708-7","article-title":"Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study","volume":"39","author":"Freeman","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023011712242342100_lam13664-bib-0018","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4161\/gmic.26854","article-title":"Clostridium difficile binary toxin CDT: mechanism, epidemiology, and potential clinical importance","volume":"5","author":"Gerding","year":"2014","journal-title":"Gut Microbes"},{"key":"2023011712242342100_lam13664-bib-0019","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1128\/AAC.01136-13","article-title":"Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 Gram-positive and Gram-negative aerobic and anaerobic intestinal flora isolates","volume":"57","author":"Goldstein","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2023011712242342100_lam13664-bib-0020","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1128\/AAC.02184-13","article-title":"Comparative in vitro activities of SMT19969, a new antimicrobial agent, against 162 strains from 35 less frequently recovered intestinal Clostridium species: implications for Clostridium difficile recurrence","volume":"58","author":"Goldstein","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023011712242342100_lam13664-bib-0021","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","article-title":"Trends in U.S. burden of Clostridioides difficile infection and outcomes","volume":"382","author":"Guh","year":"2020","journal-title":"N Engl J Med"},{"key":"2023011712242342100_lam13664-bib-0022","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ng.2478","article-title":"Emergence and global spread of epidemic healthcare-associated Clostridium difficile","volume":"45","author":"He","year":"2013","journal-title":"Nat Genet"},{"key":"2023011712242342100_lam13664-bib-0023","article-title":"Budget impact analysis of fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection in the United States","author":"Jiang","year":"2021","journal-title":"Infectious Diseases and Therapy"},{"key":"2023011712242342100_lam13664-bib-0024","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","article-title":"Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023011712242342100_lam13664-bib-0025","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/cid\/ciu313","article-title":"Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials","volume":"59","author":"Johnson","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2023011712242342100_lam13664-bib-0026","first-page":"2138","article-title":"Genome analysis of Clostridium difficile PCR ribotype 014 lineage in Australian pigs and humans reveals a diverse genetic repertoire and signatures of long-range interspecies transmission","volume":"7","author":"Knight","year":"2016","journal-title":"Front Microbiol"},{"key":"2023011712242342100_lam13664-bib-0027","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1017\/ice.2018.139","article-title":"Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting","volume":"39","author":"Lam","year":"2018","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"7","key":"2023011712242342100_lam13664-bib-0028","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00296-20","article-title":"Antimicrobial susceptibilities of Clostridium difficile isolates from 12 Asia-Pacific countries in 2014 and 2015","volume":"64","author":"Lew","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023011712242342100_lam13664-bib-0029","article-title":"Whole-genome sequencing links Clostridium (Clostridioides) difficile in a single hospital to diverse environmental sources in the community","author":"Lim","year":"2021","journal-title":"J Appl Microbiol"},{"key":"2023011712242342100_lam13664-bib-0030","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/cid\/ciu203","article-title":"Emergence of a ribotype 244 strain of Clostridium difficile associated with severe disease and related to the epidemic ribotype 027 strain","volume":"58","author":"Lim","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2023011712242342100_lam13664-bib-0031","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"2023011712242342100_lam13664-bib-0032","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nrgastro.2016.25","article-title":"Clostridium difficile infection: epidemiology, diagnosis and understanding transmission","volume":"13","author":"Martin","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2023011712242342100_lam13664-bib-0033","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1086\/511798","article-title":"Recommendations for surveillance of Clostridium difficile-associated disease","volume":"28","author":"McDonald","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2023011712242342100_lam13664-bib-0034","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023011712242342100_lam13664-bib-0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1086\/659156","article-title":"Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals","volume":"32","author":"Miller","year":"2011","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2023011712242342100_lam13664-bib-0036","volume-title":"Clostridioides difficile infection: antimicrobial prescribing [Online]","author":"NICE","year":"2021"},{"key":"2023011712242342100_lam13664-bib-0037","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1007\/s10096-021-04311-5","article-title":"Antimicrobial resistance in Clostridioides difficile","volume":"40","author":"O'Grady","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023011712242342100_lam13664-bib-0038","volume-title":"Antimicrobial resistance: Tackling a crisis for the health and wealth of nations","author":"O'Neill","year":"2014"},{"key":"2023011712242342100_lam13664-bib-0039","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.cmi.2017.12.022","article-title":"Update of treatment algorithms for Clostridium difficile infection","volume":"24","author":"Ooijevaar","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2023011712242342100_lam13664-bib-0060","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2023011712242342100_lam13664-bib-0040","doi-asserted-by":"crossref","first-page":"G227","DOI":"10.1152\/ajpgi.00046.2020","article-title":"Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids","volume":"319","author":"Qian","year":"2020","journal-title":"The American Journal of Physiology-Gastrointestinal and Liver Physiology"},{"key":"2023011712242342100_lam13664-bib-0041","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciz318","article-title":"Cost-effectiveness of treatment regimens for Clostridioides difficile infection: an evaluation of the 2018 Infectious Diseases Society of America guidelines","volume":"70","author":"Rajasingham","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023011712242342100_lam13664-bib-0042","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/jac\/dkv005","article-title":"SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI","volume":"70","author":"Sattar","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2023011712242342100_lam13664-bib-0043","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/cid\/civ958","article-title":"Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection","volume":"62","author":"Sheitoyan-Pesant","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023011712242342100_lam13664-bib-0044","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13756-020-00815-5","article-title":"Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis","volume":"9","author":"Sholeh","year":"2020","journal-title":"Antimicrobial Resistance & Infection Control"},{"key":"2023011712242342100_lam13664-bib-0045","doi-asserted-by":"crossref","first-page":"272","DOI":"10.5694\/mja13.11153","article-title":"Increasing incidence of Clostridium difficile infection, Australia, 2011\u20132012","volume":"200","author":"Slimings","year":"2014","journal-title":"Med J Aust"},{"key":"2023011712242342100_lam13664-bib-0046","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/jac\/dkab091","article-title":"Antibiotics and healthcare facility-associated Clostridioides difficile infection: systematic review and meta-analysis 2020 update","volume":"76","author":"Slimings","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023011712242342100_lam13664-bib-0047","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/jac\/dky135","article-title":"Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin","volume":"73","author":"Snydman","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023011712242342100_lam13664-bib-0048","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-3-319-72799-8_9","article-title":"Antibiotic resistances of Clostridium difficile","volume":"1050","author":"Spigaglia","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"2023011712242342100_lam13664-bib-0049","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/cid\/ciy721","article-title":"Low cure rates in controlled trials of fecal microbiota transplantation for recurrent Clostridium difficile infection: A systematic review and meta-analysis","volume":"68","author":"Tariq","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023011712242342100_lam13664-bib-0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199810","article-title":"Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin","volume":"13","author":"Thorpe","year":"2018","journal-title":"PLoS One"},{"key":"2023011712242342100_lam13664-bib-0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.anaerobe.2019.06.003","article-title":"Changes in molecular epidemiology and antimicrobial resistance profiles of Clostridioides (Clostridium) difficile strains in the United States between 2011 and 2017","volume":"60","author":"Tickler","year":"2019","journal-title":"Anaerobe"},{"key":"2023011712242342100_lam13664-bib-0052","doi-asserted-by":"crossref","first-page":"e01803","DOI":"10.1128\/mBio.01803-18","article-title":"Intrinsic class D beta-lactamases of Clostridium difficile","volume":"9","author":"Toth","year":"2018","journal-title":"MBio"},{"key":"2023011712242342100_lam13664-bib-0053","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12879-015-0759-5","article-title":"A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections","volume":"15","author":"Vickers","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2023011712242342100_lam13664-bib-0054","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijantimicag.2016.04.026","article-title":"Ridinilazole: a novel therapy for Clostridium difficile infection","volume":"48","author":"Vickers","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2023011712242342100_lam13664-bib-0055","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1473-3099(17)30235-9","article-title":"Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study","volume":"17","author":"Vickers","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2023011712242342100_lam13664-bib-0056","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1040638719899081","article-title":"Clostridium (Clostridioides) difficile in animals","volume":"32","author":"Weese","year":"2020","journal-title":"The Journal of Veterinary Diagnostic Investigation"},{"key":"2023011712242342100_lam13664-bib-0057","doi-asserted-by":"crossref","first-page":"5714","DOI":"10.1128\/AAC.02903-14","article-title":"In vivo assessment of SMT19969 in a hamster model of Clostridium difficile infection","volume":"58","author":"Weiss","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023011712242342100_lam13664-bib-0058","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa1602615","article-title":"Bezlotoxumab for prevention of recurrent Clostridium difficile infection","volume":"376","author":"Wilcox","year":"2017","journal-title":"N Engl J Med"},{"key":"2023011712242342100_lam13664-bib-0059","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/cid\/cix1021","article-title":"Attributable healthcare resource utilization and costs for patients with primary and recurrent Clostridium difficile infection in the United States","volume":"66","author":"Zhang","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["Letters in Applied Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/lam.13664","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/lam.13664","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/lambio\/article-pdf\/75\/3\/526\/48737814\/lambio0526.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/lambio\/article-pdf\/75\/3\/526\/48737814\/lambio0526.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T17:53:12Z","timestamp":1673977992000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/lambio\/article\/75\/3\/526\/6989356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1111\/lam.13664","relation":{},"ISSN":["1472-765X","0266-8254"],"issn-type":[{"value":"1472-765X","type":"electronic"},{"value":"0266-8254","type":"print"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,9,1]]}}}